Kinnate Biopharma Inc (KNTE)

Etorro trading 970x250
Kinnate Biopharma Inc (KNTE) Logo

About Kinnate Biopharma Inc

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company’s lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. Kinnate Biopharma Inc. was founded in 2018 and is headquartered in San Diego, California. Address: 11975 El Camino Real, San Diego, CA, United States, 92130

Kinnate Biopharma Inc News and around…

Latest news about Kinnate Biopharma Inc (KNTE) common stock and company :

Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates
12 May, 2022 Yahoo! Finance

Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetinib in NRAS-mutant melanoma First patient dosed in ongoing Phase 1 KN-4802 clinical trial of lead FGFR inhibitor product candidate, KIN-3248; initial data expected in the second half of 2023 Cash runway extended into early 2024, with budget reallocatio

A Kinnate Biopharma Inc. (NASDAQ:KNTE) insider increased their holdings by 1,715% last year
03 May, 2022 Yahoo! Finance

Looking at Kinnate Biopharma Inc.'s ( NASDAQ:KNTE ) insider transactions over the last year, we can see that insiders...

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248
18 Apr, 2022 Yahoo! Finance

SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the first patient has commenced treatment in its Phase 1 KN-4802 (NCT05242822) clinical trial evaluating its lead Fibroblast Growth Factor Receptor (FGFR) product candidate, KIN-3248. KIN-3248 is a next-gen

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting
08 Apr, 2022 Yahoo! Finance

Three poster presentations highlight the unmet need for targeted therapies in BRAF and/or NRAS-altered cancers, including non-small cell lung cancer and melanomaSAN FRANCISCO and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it will present data from the company’s lead

53 Biggest Movers From Yesterday
30 Mar, 2022 FinancialContent

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM ...

Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
28 Mar, 2022 Yahoo! Finance

Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the combination portion of KN-8701 to study KIN-2787 with binimetinib in NRAS-mutant melanoma expected in the first half of 2022 with initial data expected by year end 2022 Cash, cash equivalents and investments of approximately $324.9 million as of December 31, 2021, exclusive of its China joint venture’s c

Implied VTWG Analyst Target Price: $256
22 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $256.34 per unit.

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting
08 Mar, 2022 Yahoo! Finance

Poster presentations to highlight data from ongoing studies of the company’s lead Pan-RAF kinase inhibitor program, KIN-2787SAN FRANCISCO and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced abstracts highlighting the company’s lead RAF kinase inhibitor program, KIN-2787, have

Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress
07 Mar, 2022 Yahoo! Finance

Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the presentation of findings from a collaborati

Noteworthy Thursday Option Activity: MU, MDB, KNTE
03 Mar, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Micron Technology Inc. (MU), where a total volume of 164,312 contracts has been traded thus far today, a contract volume which is representative of approximately 16.4 million underlying shares (given that every 1 contract represents 100 underlying shares)..

Kinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care Conference
28 Feb, 2022 Yahoo! Finance

SAN FRANCISCO and SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 42nd Annual Cowen Health Care Conference, being held virtually from March 7-9, 2022. Event: 42nd Annual Cowen Health Care Confer

Stocks That Hit 52-Week Lows On Monday
28 Feb, 2022 FinancialContent

On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) ...

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans
26 Feb, 2022 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysts Predict 27% Upside For The Holdings of VTWV
18 Feb, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $174.42 per unit.

Wednesday 2/16 Insider Buying Report: KNTE, AMG
16 Feb, 2022 FinancialContent

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting
14 Feb, 2022 Yahoo! Finance

Presentation to focus on antitumor activity of KIN-2787 in preclinical models of human BRAF-alteration driven non-small cell lung cancerSAN FRANCISCO and SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it has been selected to deliver an oral presentation of preclinical dat

Gabelli Convertible and Income Securities Fund Declares First Quarter Distribution of $0.12 Per Share
09 Feb, 2022 Yahoo! Finance

RYE, N.Y., February 09, 2022--The Board of Directors of The Gabelli Convertible and Income Securities Fund Inc. (NYSE:GCV) (the "Fund") declared a $0.12 per share cash distribution payable on March 24, 2022 to common stock shareholders of record on March 17, 2022.

Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
07 Feb, 2022 Yahoo! Finance

SAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. Event: 11th Annual SVB Lee

Stocks That Hit 52-Week Lows On Friday
04 Feb, 2022 FinancialContent

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta ...

Stocks That Hit 52-Week Lows On Thursday
03 Feb, 2022 FinancialContent

On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And ...

Stocks That Hit 52-Week Lows On Tuesday
25 Jan, 2022 FinancialContent

On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse ...

52 Biggest Movers From Yesterday
20 Jan, 2022 FinancialContent

Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be ...

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium
19 Jan, 2022 Yahoo! Finance

Presentation to highlight data from preclinical studies of the company’s next-generation pan-FGFR inhibitor, KIN-3248, and its activity against acquired FGFR gatekeeper and molecular brake drug-resistance mutationsSAN FRANCISCO and SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the

Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
18 Jan, 2022 Yahoo! Finance

Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022SAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the U.S Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for KIN-3248, a next-generat

Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones
06 Jan, 2022 Yahoo! Finance

Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant melanoma in monotherapy and initiation of a combination portion with binimetinib planned for first half of 2022 Announces planned initiation of Phase 1 trial of KIN-3248 for first half of 2022 subject to IND clearance by the FDA Updated cash, cash equivalents and investments of approximately $324.9 mill

Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
21 Dec, 2021 Yahoo! Finance

Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc.

Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings
20 Dec, 2021 Yahoo! Finance

AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors ASCO GI Cancers Symposium presentation will highlight results from preclinical studies evaluating the company’s lead Fibroblast Growth Factor Receptor (FGFR) inhibitor candidate, KIN-3248 SAN FRANCISCO and SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopha

How The Pieces Add Up: VTWV Headed For $172
17 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $172.23 per unit.

Kinnate Biopharma is Now Oversold (KNTE)
16 Dec, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Kinnate Biopharma Inc. Announces Addition to NASDAQ Biotechnology Index
16 Dec, 2021 Yahoo! Finance

SAN FRANCISCO and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (“NBI”). Kinnate’s addition to the NBI will become effective prior to market open on Monday, December 20, 2021. The NBI is designed to trac

Kinnate Biopharma Inc (KNTE) is a NASDAQ Common Stock listed in , ,

970x250